| Identification | Back Directory | [Name]
1H-Imidazole-5-carboxamide, 4-(1H-benzimidazol-2-yl)-N-cyclohexyl- | [CAS]
2755454-90-9 | [Synonyms]
Autophagy-IN-2
1H-Imidazole-5-carboxamide, 4-(1H-benzimidazol-2-yl)-N-cyclohexyl- | [Molecular Formula]
C17H19N5O | [MOL File]
2755454-90-9.mol | [Molecular Weight]
309.37 |
| Hazard Information | Back Directory | [Uses]
Autophagy-IN-2 (Compound 7h) is an autophagic flux inhibitor. Autophagy-IN-2 induces cancer cell apoptosis and can be used for triple-negative breast cancer research[1]. | [in vivo]
Autophagy-IN-2 (Compound 7h) (5 and 15 mg/kg; i.p.; every 3 days for 3 weeks) suppresses tumor growth in a dose-dependent manner[1]. | Animal Model: | Six-week-old female NOD/SCID mice, MDA-MB-231 xenograft[1] | | Dosage: | 5 mg/kg, 15 mg/kg | | Administration: | Intraperitoneal injection, every 3 days for 3 weeks | | Result: | Suppressed human TNBC tumor growth in a dose-dependent manner and resulted in a concentration-dependent upregulation of LC3B-II, p62, γH2AX and PARP. |
| [References]
[1] Yang DL, et al. Discovery of fused benzimidazole-imidazole autophagic flux inhibitors for treatment of triple-negative breast cancer. Eur J Med Chem. 2022 Jun 26;240:114565. DOI:10.1016/j.ejmech.2022.114565 |
|
|